

# Effect of glucagon-like-peptide-1 (GLP-1) on left ventricular function during percutaneous coronary intervention (PCI)

<b>Submission date</b> 23/04/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 23/04/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 27/01/2016	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Phil Read

### Contact details

Addenbrooke's Hospital  
Wellcome Trust MRC Building  
Cambridge  
United Kingdom  
CB2 0XY

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

### Secondary identifying numbers

6979; G0701720

# Study information

## Scientific Title

Investigation of the effect of glucagon-like-peptide-1 (GLP-1) on left ventricular function during elective coronary angioplasty and stenting

## Study objectives

Assessment of the cardioprotective effects of glucagon-like-peptide-1 (GLP-1) from ischaemia during coronary angioplasty.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Hertfordshire Research Ethics Committee, 24/04/2009, ref: 09/H0311/17

## Study design

Randomised interventional treatment trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

## Interventions

Assessment of left ventricular function during coronary angioplasty. In the active arm patients will receive an intravenous infusion of glucagon-like peptide-1 at 1.2 pmol/kg/min which will start after the 1st balloon inflation in the coronary artery and will run until the end of the procedure. In the control arm there will be no infusion.

## Intervention Type

Drug

## Phase

Not Applicable

**Drug/device/biological/vaccine name(s)**

Glucagon-like-peptide-1

**Primary outcome measure**

Left ventricular function with and without GLP-1, measured during two balloon inflations in the coronary artery which are 30 minutes apart

**Secondary outcome measures**

1. Collateral flow with and without GLP-1
2. Troponin I at 24 hours

Measured during two balloon inflations in the coronary artery which are 30 minutes apart.

**Overall study start date**

22/05/2009

**Completion date**

01/05/2012

## **Eligibility**

**Key inclusion criteria**

1. Age over 18 (male or female and no upper age limit)
2. Able to give informed consent
3. On the waiting list for elective PCI to a single vessel coronary stenosis
4. Normal left ventricular function

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

Planned Sample Size: 40

**Key exclusion criteria**

1. Atrial fibrillation
2. Myocardial infarction less than 3 months previously
3. Previous coronary artery bypass grafts
4. Treatment with insulin, sitagliptin, vildagliptin or exenatide

**Date of first enrolment**

22/05/2009

**Date of final enrolment**

01/05/2012

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Addenbrooke's Hospital**

Cambridge

United Kingdom

CB2 0XY

## **Sponsor information**

**Organisation**

Papworth Hospital NHS Foundation Trust (UK)

**Sponsor details**

Papworth Everard

Cambridge

England

United Kingdom

CB3 8RE

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.papworthhospital.nhs.uk/index.php>

**ROR**

<https://ror.org/01qbebb31>

## **Funder(s)**

**Funder type**

Research council

**Funder Name**

Medical Research Council (MRC) (UK) (ref: G0701720)

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	pilot study results	01/06/2011		Yes	No
<a href="#">Results article</a>	results	01/02/2015		Yes	No